Armata Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $141.7M
- Price
- $3.81
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.04%
- Volume
- 103.7K
About
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Quick stats
Shares outstanding37.2M
Computed float20.3M
Float / shares54.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000921114
Websitehttps://www.armatapharma.com
AI Summary
AI-generated1/15
minorbullishoperations update
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Armata Pharmaceuticals received an additional $3.7 million in non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02 for complicated Staphylococcus aureus bacteremia.
The funds mark the first tranche specifically dedicated to Phase 3 execution under the previously announced DoW award, bringing cumulative non-dilutive support to approximately $32.4 million.
Management said it intends to work with the DoW on potential additional support as the Phase 3 study advances, with the pivotal trial anticipated to initiate in the second half of 2026.